Biliary tract cancer outcomes not improved by addition of nab-paclitaxel to standard care.
Annual scientific meetings are off to a big start in 2023 with the 20 year celebratory ASCO GI Symposium held in San Francisco in January.
In the field of rare gastrointestinal cancers, biliary tract cancer updates included a report from the late phase SWOG-1815 clinical trial designed to inform management of advanced disease.
SWOG-1815 overall survival results were presented, with this Phase III study conducted through the National Clinical Trials Network completing recruitment in a rare cancer population (cholangiocarcinoma and gallbladder carcinoma). Overall survival and progression-free survival results were not statistically significant for the addition of nab-paclitaxel to cisplatin gemcitabine in the overall population, with subgroup exploratory analysis identifying trend towards longer survival in the gallbladder cancer (underpowered).
A previous single arm Phase II study found a median overall survival of 19.2 months for this triplet regimen in advance biliary tract cancer, and the successful completion of a subsequent Phase III study is an important undertaking in these rare cancers to optimally inform routine clinical practice.
More information
You can read the whole abstract and others via the ASCO website:
Learn more